Pharmacokinetics and systemic action
Sulfacarbamide (Urosulfanum) belongs to the group of sulfonamide drugs (quinolone and 8-hydroxyquinoline derivatives) intended for resorptive action. This means that after oral administration, the drug is characterized by good gastrointestinal absorption, enters the systemic circulation, and exerts a generalized effect.
According to the pharmacokinetic classification based on the half-life ($t_{1/2}$), sulfacarbamide is included in the subgroup of short-acting drugs ($t_{1/2} < 10$ hours).
A key feature of sulfacarbamide metabolism is that it undergoes low acetylation in the body. Unlike many other sulfonamides, it is excreted by the kidneys predominantly in its unchanged (free) form.
Indications for use
The primary target for prescribing the drug is urinary tract infections (UTIs).
Since the drug is excreted by the kidneys in an unchanged form, it does not lose its antibacterial activity during metabolism. This allows for consistently high active concentrations of the substance directly in the urine, providing a reliable therapeutic effect at the infection site. Sulfethidole (ethazole) shares a similar property within the short-acting drug group — both of these agents are drugs of choice for UTIs.
Dosage Regimen and Formulations
The short half-life (less than 10 hours) necessitates frequent administration of the drug to maintain therapeutic concentrations in the blood and urine. Sulfacarbamide is prescribed frequently — 4–6 times a day.
The drug is available as a powder and 0.5 g tablets.
Oral administration guidelines:
- The drug is taken 30 minutes before meals.
- First day of treatment: a loading dose is prescribed — the initial dose is 1.5–2.0 g. Then, switch to a maintenance dose of 1.0 g every 4 hours.
- From the second day of treatment: the dosage is reduced to 1.0 g 4 times a day.
- Dosage limitations: the maximum single dose (MSD) is 2.0 g, and the maximum daily dose (MDD) is 7.0 g.
Place in the sulfonamide classification
To understand the pharmacokinetics of sulfacarbamide, it is important to consider its place in the general classification of sulfonamides for resorptive action. Drugs in this group are categorized by their half-life ($t_{1/2}$):
- Short-acting ($t_{1/2} < 10$ h): in addition to sulfacarbamide (Urosulfanum), this includes sulfanilamide (streptocide), sulfathiazole (norsulfazole), sulfethidole (ethazole), and sulfadimidine (sulfadimezine). They require frequent administration.
- Intermediate-acting ($t_{1/2}$ 10–24 h): sulfadiazine (sulfazine) and sulfamethoxazole.
- Long-acting ($t_{1/2}$ 24–48 h): sulfadimetoxine, sulfamonomethoxine, sulfamethoxypyridazine.
- Ultra-long-acting ($t_{1/2} > 48$ h): sulfalene.
Thus, sulfacarbamide represents a classic short-acting systemic agent requiring strict adherence to dosing intervals.
Briefly: answers to topical questions
What is the mechanism of action of sulfacarbamide on the bacterial cell?
The mechanism of action of sulfacarbamide involves competitive antagonism with para-aminobenzoic acid (PABA) for binding to dihydropteridine. The drug acts at the earliest stage of synthesis, causing enzymatic blockade of dihydropteroate synthase. This leads to disruption of bacterial intracellular metabolism:
- Blockade of formation — prevents the synthesis of dihydropteroic acid.
- Disruption of synthesis — blocks the step of converting PABA into dihydrofolic acid, which is a precursor of folic acid necessary for nucleotide synthesis.
Selectivity of action is ensured by the fact that mammalian cells do not express this target enzyme.
What is the spectrum of antibacterial activity of sulfacarbamide?
Sulfacarbamide has a broad spectrum of antimicrobial activity. It is effective against Gram-positive and Gram-negative bacteria, including aerobic and anaerobic microorganisms. The most sensitive pathogens include: Haemophilus influenzae, Neisseria meningitidis, pneumococci, and certain strains of Bacteroides.
What side effects can occur when taking sulfacarbamide?
Sulfacarbamide is a relatively safe drug, and the risk of side effects is low. The high safety profile for the host organism is explained by the mechanism of selectivity: mammalian cells do not express the target enzyme (dihydropteroate synthase), and therefore are not affected by sulfonamides. The only specified risk factor is the patient's age — use of the drug may cause side effects in newborns. Specific manifestations of adverse reactions are not described in the provided materials.
Urosulfan works in Urology: it remains unchanged in the liver (low acetylation) and attacks the infection directly in the urine.
Class and exam questions
Why is sulfacarbamide prescribed specifically for urinary tract infections?
It is excreted by the kidneys in an unchanged form (undergoes little acetylation), creating high concentrations of the active antibacterial substance in the urine.
Which duration-of-action group does the drug belong to?
It is a short-acting sulfonamide. Its half-life ($t_{1/2}$) is less than 10 hours.
How often should sulfacarbamide be taken?
Due to its short half-life, the drug requires frequent administration — 4–6 times a day (every 4 hours on the first day of treatment).
What else to study on this topic
- Classification of sulfonamides by duration of action
- The process of sulfonamide acetylation and its clinical significance
- Comparative pharmacokinetics of urosulfan and ethazole
- Principles of dosing short-acting sulfonamides
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Sulfacarbamide" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.